Assessing unmet need among elderly Medicare Beneficiaries with Mantle cell lymphoma: an analysis of treatment patterns, survival, healthcare resource utilization, and costs
Open Access
- 27 July 2023
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 64 (11) , 1752-1770
Abstract
Studies evaluating real-world outcomes and health care utilization for mantle cell lymphoma are limited. We utilized national Medicare claims (2009-2019) to examine treatment patterns, healthcare resource utilization, costs, and survival in 3664 elderly patients receiving 1 L treatment for MCL. Over a median follow-up of 2.8 years, 40.3% received at least 2 L treatment. The most common 1 L regimen was bendamustine-rituximab (50.1%), with increased use of BTKi-based regimens observed in 2 L (39.4%). Half (51.8%) of patients had an all-cause hospitalization within 12 months of initiating 1 L; hospitalization rates were higher in later lines. Healthcare costs were substantial and most costs (>80%) were MCL-related. Overall survival was poorer among later lines of treatment (median OS from initiation of 1 L: 53.5 months; 2 L: 22.0 months; 3 L: 11.8 months; 4 L: 7.8 months). These results suggest a large unmet need and future work should evaluate whether novel therapies have improved outcomes among elderly patients with MCL.Keywords
This publication has 23 references indexed in Scilit:
- Treatment patterns and outcomes among mantle cell lymphoma patients treated with ibrutinib in the United States: a retrospective electronic medical record database and chart review studyBritish Journal of Haematology, 2020
- Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United StatesCancer Medicine, 2019
- Adverse events, resource use, and economic burden associated with mantle cell lymphoma: a real-world assessment of privately insured patients in the United StatesLeukemia & Lymphoma, 2018
- Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapyHaematologica, 2018
- Frontline Treatment for Older Patients with Mantle Cell LymphomaThe Oncologist, 2018
- Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trialThe Lancet, 2018
- Bendamustine–rituximab in mantle cell lymphomaThe Lancet Haematology, 2016
- Treatment of Older Patients with Mantle-Cell LymphomaNew England Journal of Medicine, 2012
- Outcome of Deferred Initial Therapy in Mantle-Cell LymphomaJournal of Clinical Oncology, 2009
- Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004Cancer, 2008